New Study Touts Benefits of Organic Goods, Questions Pesticides and GMOs
Though not earth-shattering, the largest study to date represents a continued move away from chemical use.
Regeneron's $4.7 Billion Opportunity
Regeneron recently got some good news. Check out the video below for more information.
Why Are These 3 Dow Jones Stocks Crushing the Market in 2014?
Intel, Caterpillar, and Merck were the Dow's best performers in the first half of 2014. Why did these three stocks race ahead, and where are they going next?
Why OncoMed Pharmaceuticals Inc. Shares Collapsed
OncoMed shares dive after it voluntarily halts two early-stage programs. Find out what investors should be closely monitoring going forward.
Wednesday’s Top Biotech Stories: Orexigen, Portola, and Regeneron
Orexigen, Portola, and Regeneron could all make waves across the health care sector this Wednesday morning.
Good News at Boston Scientific: What's Next
Three recent developments help Boston Scientific, but don't fundamentally alter the thesis
Does This Study Prove Monsanto Company is Killing Our Honey Bees?
A class of insecticides has long been claimed to be at the root of the demise of honey bee populations. Do the data show that Monsanto, Bayer, and Syngenta are to blame?
Monday’s Top Health Care Stories: AstraZeneca, Pfizer, Intermune, and Compugen
AstraZeneca, Pfizer, Intermune, and Compugen could loom large in health care headlines this Monday morning.
Boston Scientific to Spend $415 Million on Bayer Division
Bayer says the sale will allow its health care unit to focus on growing its radiology and diabetes care segments.